Author:
Laban Marija,Omčikus Maja,Đikić Marina,Marković Filip,Dalifi Sead
Abstract
Due to the increasing use of immunosuppressants, particularly biological therapy, as well as HIV epidemics, latent tuberculosis (LTBI) is being activated, and this disease, which had been rather forgotten in the Western world, is becoming a topical issue in the recent years. Numerous categories of patients should be tested for latent tuberculosis, using PPD or IGRA tests. Interpreting test results is a very touchy issue, since it is the way to determine therapy of latent TB, that is, to decide on chemoprophylaxis. For the last two years, during the Covid-19 pandemics, large percentage of patients received high doses of corticosteroid and other types of immunosuppressant therapies, and it is therefore necessary to consider the potential risks for these patients, in terms of contracting tuberculosis and perhaps testing them for LTBI.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference13 articles.
1. Snowden FM. Emerging and reemerging diseases: A historical perspective.;
2. Uplekar M, Weil D, Lonnroth K, Jaramilo E, Leinhardt C, Dias HM, et al. WHO s new end TB strategy. Lancet. 2015; 385(9979): 1799-801.;
3. Latentna tuberkuloza -smernice za dijagnostiku latentne tuberkuloze sa primerima iz kliničke prakse. Klinika za pulmologiju Kliničkog centra Srbije, Respiratorno udruženje Srbije, Beograd, 2019.;
4. Uputa za upotrebu proizvoda QuantiFERON -TB Gold Plus (QFT -Plus) ELISA.;
5. Tubach F, Salmon D, RavAUD P et al. Risk for tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-94.;